Houston Methodist (The Woodlands) Internal Medicine

Topics

• Acute Myeloid Leukemia Research 10
• Pulmonary Hypertension Research and Treatments 7
• Protein Degradation and Inhibitors 6
• Acute Lymphoblastic Leukemia research 5
• Antifungal resistance and susceptibility 5
• CAR-T cell therapy research 4
• Colorectal Cancer Surgical Treatments 3
• COVID-19 and healthcare impacts 3
• Neutropenia and Cancer Infections 3
• Advanced Radiotherapy Techniques 2
• Esophageal Cancer Research and Treatment 2
• Head and Neck Cancer Studies 2

Most cited

1. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.

   Nature medicine · 2023 · 334 citations · Qi Tatarata

2. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.

   Signal transduction and targeted therapy · 2022 · 177 citations · Qi Tatarata

3. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.

   Blood · 2023 · 115 citations · Qi Tatarata

4. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.

   Haematologica · 2021 · 123 citations · Qi Tatarata

5. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.

   Nature communications · 2021 · 121 citations · Qi Tatarata

6. Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.

   Blood · 2025 · 24 citations · Qi Tatarata